Human Mixtard 50/50 Injection 40 IU 10ml Vial

Human Mixtard 50/50 Injection 40 IU ml vial is a combination of drugs containing equal proportions of acting human insulin (50%) and intermediate-acting insulin isophane (50%), used to provide both immediate and sustained blood glucose control in patients with diabetes mellitus. The medication is used to treat diabetes mellitus type 1 and type 2 to improve blood sugar in both adults and children. A doctor's prescription is highly recommended for the treatment. Follow the recommended dosage as directed by the healthcare professional.

• Improve blood sugar level

Human mixtard 50/50 Injection caused side effects like any other medication. It can be taken under a doctor's prescription to avoid complications during the treatment. Common side effects include:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at the injection site.

Human mixtard 50/50 Injection 40 IU ml can be taken under a doctor's prescription to improve the effectiveness of the treatment. The medicine should be taken before or after a meal, with the dose and timing adjusted according to the blood glucose levels, diet, and overall medical condition. Never self-administer; follow the recommended dosage as prescribed by the healthcare professional.

Human mixtard 50/50 Injection 40 IU ml contains two active drugs that help to manage blood sugar in the human body. The insulin in the injection binds to receptors on muscle and fat cells, which facilitate the uptake of glucose (sugar) from the bloodstream into these cells, where it is used for energy or stored. It suppresses the production of new sugar by the liver (hepatic glucose production). The medication is administered under a doctor's prescription.

• Mudaliar, S. R., Lindberg, F. A., Joyce, M., Beerdsen, P., Strange, P., Lin, A., & Henry, R. R. (1999). Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes care, 22(9), 1501-1506.  https://pubmed.ncbi.nlm.nih.gov/10480516/
• Fullerton, B., Siebenhofer, A., Jeitler, K., Horvath, K., Semlitsch, T., Berghold, A., ... & Cochrane Metabolic and Endocrine Disorders Group. (1996). Short‐acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database of Systematic Reviews, 2019(6). https://pubmed.ncbi.nlm.nih.gov/27362975/
• Heinemann, L., & Richter, B. (1993). Clinical pharmacology of human insulin. Diabetes Care, 16(Supplement_3), 90-100. https://pubmed.ncbi.nlm.nih.gov/8299482/
• Owens, D. R. (1986). Human insulin: clinical pharmacological studies in normal man. Springer Science & Business Media.  https://pubmed.ncbi.nlm.nih.gov/6133710/
• Barnett, A. H., & Owens, D. R. (1997). Insulin analogues. The Lancet, 349(9044), 47-51. https://pubmed.ncbi.nlm.nih.gov/8988131/